François Chomy
François Chomy is an expert in Oncology at Institut Bergonié (France). François Chomy has authored 37 publications, the most recent in 2023, and is an investigator in 4 clinical trials. SLR score: 91 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2006 - 2023
Number : 37
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer. PMID 38048058 — cells, lung, progression-free survival, antigens, surface, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, tissues, t-lymphocytes, plasma, chemotherapy | Clin Cancer Res | 2023 | 14 |
| Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer. PMID 37756581 — cells, up-regulation, lung, dioxygenases, progression-free survival, tryptophan, neoplasms, kynurenine, carcinoma, non-small-cell lung, tertiary lymphoid structures, lung neoplasms, enzymes, small cell lung carcinoma, t-lymphocytes, b-lymphocytes, indoleamine-pyrrole 2,3,-dioxygenase | Clin Cancer Res | 2023 | 7 |
| Evaluating video-based consultations in routine clinical practice at a comprehensive cancer center. PMID 37948066 — physics, neoplasms, telemedicine, radiation effects, physicians, medical oncology | Acta Oncol | 2023 | 1 |
| Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. PMID 35850444 — plasma, biomarkers, cells, therapeutics, neoplasms, t-lymphocytes, disease-free survival, arginine, progression-free survival, immune checkpoint inhibitors | Ann Oncol Top journal | 2022 | 46 |
| Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial. PMID 35802649 — cells, lung, progression-free survival, neoplasms, carcinoma, non-small-cell lung, genome, maintenance, lung neoplasms, small cell lung carcinoma, precision medicine, therapeutics | Clin Cancer Res | 2022 | 7 |
Clinical Studies 4
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map